MX2009009119A - Metodo para tratar o prevenir la inflamacion sistemica. - Google Patents

Metodo para tratar o prevenir la inflamacion sistemica.

Info

Publication number
MX2009009119A
MX2009009119A MX2009009119A MX2009009119A MX2009009119A MX 2009009119 A MX2009009119 A MX 2009009119A MX 2009009119 A MX2009009119 A MX 2009009119A MX 2009009119 A MX2009009119 A MX 2009009119A MX 2009009119 A MX2009009119 A MX 2009009119A
Authority
MX
Mexico
Prior art keywords
treating
systemic inflammation
preventing systemic
subject
preventing
Prior art date
Application number
MX2009009119A
Other languages
English (en)
Inventor
Robert J Mcmahon
Josef Neu
Udo Herz
William Michael Russell
Original Assignee
Mead Johnson Nutrition Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39469924&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009009119(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mead Johnson Nutrition Co filed Critical Mead Johnson Nutrition Co
Publication of MX2009009119A publication Critical patent/MX2009009119A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención está dirigida a un método nuevo para tratar o prevenir inflamación sistémica en un sujeto. El método administra al sujeto una cantidad terapéuticamente eficaz de LGG inactivado.
MX2009009119A 2007-02-28 2008-02-22 Metodo para tratar o prevenir la inflamacion sistemica. MX2009009119A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90412207P 2007-02-28 2007-02-28
PCT/US2008/054710 WO2008106372A1 (en) 2007-02-28 2008-02-22 Method for treating or preventing systemic inflammation

Publications (1)

Publication Number Publication Date
MX2009009119A true MX2009009119A (es) 2009-09-04

Family

ID=39469924

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2009008875A MX2009008875A (es) 2007-02-28 2008-02-22 Producto que contiene probiotico inactivado para niños o infantes.
MX2009009119A MX2009009119A (es) 2007-02-28 2008-02-22 Metodo para tratar o prevenir la inflamacion sistemica.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2009008875A MX2009008875A (es) 2007-02-28 2008-02-22 Producto que contiene probiotico inactivado para niños o infantes.

Country Status (14)

Country Link
US (2) US9408819B2 (es)
EP (2) EP2124977B9 (es)
CN (3) CN101678053B (es)
AT (1) ATE544457T1 (es)
BR (2) BRPI0808052A2 (es)
CA (2) CA2679374C (es)
ES (2) ES2388198T5 (es)
HK (2) HK1136969A1 (es)
MX (2) MX2009008875A (es)
MY (2) MY151892A (es)
PL (2) PL2124977T3 (es)
RU (2) RU2468808C2 (es)
TW (2) TWI494114B (es)
WO (2) WO2008106372A1 (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7767203B2 (en) 1998-08-07 2010-08-03 Ganeden Biotech, Inc. Methods for the dietary management of irritable bowel syndrome and carbohydrate malabsorption
ES2388198T5 (es) * 2007-02-28 2020-07-14 Mjn Us Holdings Llc Lactobacillus Rhammosus GG inactivado para tratar la inflamación sistémica en bebés
AU2008333718B2 (en) * 2007-12-06 2012-03-15 Arla Foods Amba Probiotic bacteria and regulation of fat storage
CN102202527B (zh) * 2008-11-03 2014-12-31 雀巢产品技术援助有限公司 包含益生菌并改善睡眠模式的营养组合物
JP5836264B2 (ja) * 2009-04-29 2015-12-24 ガネーデン バイオテック インコーポレイテッド 不活性化細菌細胞製剤
EP2251020A1 (en) * 2009-05-11 2010-11-17 Nestec S.A. Short-time high temperature treatment generates microbial preparations with anti-inflammatory profiles
EP2251022A1 (en) * 2009-05-11 2010-11-17 Nestec S.A. Non-replicating micro-organisms and their immune boosting effect
CA2761444C (en) * 2009-05-11 2018-04-24 Nestec S.A. Lactobacillus johnsonii la1 ncc533 (cncm i-1225) and immune disorders
BR112012017978A2 (pt) * 2010-01-19 2016-05-03 Abbott Lab fórmulas nutricionais contendo simbióticos
US9301982B2 (en) 2010-04-14 2016-04-05 Ganeden Biotech, Inc. Probiotic confection and lipid compositions
RU2593716C2 (ru) * 2010-11-11 2016-08-10 Нестек С.А. Замороженные кондитерские изделия, содержащие пробиотические микроорганизмы
EP2455093A1 (en) * 2010-11-11 2012-05-23 Nestec S.A. Non-replicating probiotic bacteria and prevention or treatment of infections in children
EP2455094A1 (en) 2010-11-11 2012-05-23 Nestec S.A. Non-replicating probiotic micro-organisms protect children against gastrointestinal infections
EP2455092A1 (en) * 2010-11-11 2012-05-23 Nestec S.A. Non-replicating probiotic micro-organisms protect against upper respiratory tract infections
EP2452576A1 (en) * 2010-11-11 2012-05-16 Nestec S.A. Extruded non-replicating probiotic micro-organisms and their health benefits
WO2012135499A1 (en) 2011-03-31 2012-10-04 Ganeden Biotech, Inc. Probiotic sports nutrition compositions
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
KR101166798B1 (ko) 2011-12-19 2012-07-26 김대현 락토바실러스 애시도필러스 엘비의 사균을 포함하는 알레르기 질환의 치료 또는 예방용 의약 조성물
WO2013103826A1 (en) * 2012-01-06 2013-07-11 Skyview Enterprise Ltd. Anti-inflammatory compounds in combination with hydrogen for the treatment of inflammation
US20130251829A1 (en) * 2012-03-23 2013-09-26 Mead Johnson Nutrition Company Probiotic derived non-viable material for infection prevention and treatment
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
CN105555283B (zh) * 2013-08-09 2020-08-11 Ab-生物股份有限公司 用于婴儿过度啼哭的益生菌
US20160303226A1 (en) * 2013-11-25 2016-10-20 Nestec S.A. Heat-treated formulation of bifidobacterium lactis ncc 2818 reduces allergic manifestations
MX2016006574A (es) * 2013-11-29 2016-08-03 Nestec Sa Composiciones nutritivas adaptadas a la edad con un contenido de proteina variable.
DK3065748T3 (da) 2014-12-23 2018-01-29 4D Pharma Res Ltd En bacteroides thetaiotaomicron stamme og dens anvendelse til reduktion af inflammation
NO3193901T3 (es) 2014-12-23 2018-09-01
SI3650033T1 (sl) 2015-06-15 2022-05-31 4D Pharma Research Limited Sestavki, ki obsegajo bakterijske seve
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
EP3636272A1 (en) 2015-06-15 2020-04-15 4D Pharma Research Limited Compositions comprising bacterial strains
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
TW202222339A (zh) 2015-06-15 2022-06-16 英商4D製藥研究有限公司 包含細菌菌株之組合物
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
MX2018006240A (es) 2015-11-20 2018-08-01 4D Pharma Res Ltd Composiciones que comprenden cepas bacterianas.
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
SI3313423T1 (sl) 2016-03-04 2019-07-31 4D Pharma Plc Sestavki, ki vsebujejo bakterijske seve Blautia za zdravljenje visceralne preobčutljivosti
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
TW201821093A (zh) 2016-07-13 2018-06-16 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
ES2657665B1 (es) * 2016-09-05 2018-12-17 Pedro Jose DE LA FUENTE BLASCO Productos para la salud con probióticos inactivados y uso de dichos productos
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
CN107115362A (zh) * 2017-04-28 2017-09-01 青岛东海药业有限公司 凝结芽孢杆菌在制备预防或治疗支气管哮喘制剂中的应用
DK3630136T3 (da) 2017-05-22 2021-05-25 4D Pharma Res Ltd Sammensætninger, der omfatter bakteriestammer
MA41708A (fr) 2017-05-24 2020-04-08 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
LT3638271T (lt) 2017-06-14 2021-01-11 4D Pharma Research Limited Kompozicijos, apimančios bakterines padermes
EP4104843A1 (en) 2017-06-14 2022-12-21 4D Pharma Research Limited Compositions comprising bacterial strains
CN108041607A (zh) * 2017-12-26 2018-05-18 广州普正生物科技有限公司 一种护齿益生菌咀嚼软胶囊
RU2770463C1 (ru) * 2020-10-14 2022-04-18 федеральное государственное бюджетное образовательное учреждение высшего образования "Алтайский государственный технический университет им. И.И. Ползунова" (АлтГТУ) Способ производства мягкого сыра
TWI802009B (zh) * 2021-09-16 2023-05-11 創百股份有限公司 使用熱致死的乳酸菌菌株來治療和/或預防微粒物質-誘發的肺損傷

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804179A (en) * 1985-12-31 1998-09-08 Research Corporation Technologies, Inc. Lactobacillus compositions and methods for treating urinary tract infections
US6156320A (en) * 1993-02-05 2000-12-05 Harry Parsekian Fermented milk nutraceuticals
RU2031586C1 (ru) * 1993-02-05 1995-03-27 Тамара Георгиевна Извекова Биологически активный кисломолочный продукт "ацидолакт-наринэ" и способ его получения
US6180100B1 (en) * 1994-09-30 2001-01-30 Urex Biotech., Inc. Lactobacillus compositions and methods for treating urinary tract infections
FI104465B (fi) * 1995-06-14 2000-02-15 Valio Oy Proteiinihydrolysaatteja allergioiden hoitamiseksi tai estämiseksi, niiden valmistus ja käyttö
EP0965643B1 (en) * 1998-06-17 2003-11-05 Societe Des Produits Nestle S.A. Mobile genetic elements as tools for genetic modification of L. delbrueckii or L. helveticus
US6399055B1 (en) * 1998-10-27 2002-06-04 Compagnie Gervais Danone Method and composition for treatment of infant diarrhea
ID30071A (id) * 1998-12-11 2001-11-01 Urex Biotech Inc Pemberian oral lactobacillus untuk pengobatan dan pencegahan infeksi urogental
ID29150A (id) * 1999-01-15 2001-08-02 Entpr Ireland Cs Penggunaan lactobacillus salivarius
WO2001058465A2 (en) * 2000-02-10 2001-08-16 Gregor Reid Probiotic therapy for newborns
MXPA03005465A (es) * 2000-12-18 2004-10-14 Probiohealth Llc Compuestos probioticos derivados de la cepa ke01 de lactobacillus casei.
KR100419132B1 (ko) * 2000-12-29 2004-02-18 조성근 위·장 점막 부착성과 증식성, 내산성, 내담즙성 및헬리코박터 파일로리, 대장균 0157:ｈ7에 대한 항균성이우수한 락토바실러스 파라카제이 서브스패시즈 파라카제이ｃｓｋ 01
FI109602B (fi) * 2001-01-25 2002-09-13 Valio Oy Probioottiyhdistelmä
NZ527493A (en) * 2001-02-06 2005-06-24 Nestle Sa Endotoxin binding by lactobacillus and bifidobacteria having hydrophobic surface properties and use of the bacteria in treating endotoxin ( LPS ) mediated disorders
PE20030283A1 (es) * 2001-07-26 2003-05-01 Alimentary Health Ltd Cepas de lactobacillus casei
PE20030284A1 (es) * 2001-07-26 2003-05-01 Alimentary Health Ltd Cepas de bifidobacterium
PE20030274A1 (es) * 2001-07-26 2003-05-08 Alimentary Health Ltd Cepas de lactobacillus salivarius
EP1364586A1 (en) * 2002-05-24 2003-11-26 Nestec S.A. Probiotics and oral tolerance
US20050100531A1 (en) * 2002-06-13 2005-05-12 John Bienenstock Probiotic therapies
PT1565547E (pt) * 2002-06-28 2008-11-03 Puleva Biotech Sa Estirpes probióticas, processo para a sua selecção, suas composições e sua utilização
US20040208863A1 (en) * 2003-01-30 2004-10-21 James Versalovic Anti-inflammatory activity from lactic acid bacteria
US20050180962A1 (en) * 2003-01-30 2005-08-18 Eyal Raz Inactivated probiotic bacteria and methods of use thereof
EP1608383A1 (en) * 2003-03-31 2005-12-28 Alimentary Health Limited A formulation comprising a bacterial strain
EP1638415B1 (en) * 2003-06-23 2010-12-15 Nestec S.A. Infant or follow-on formula
US7125963B2 (en) * 2004-03-03 2006-10-24 En N Tech Inc Treatments for contaminant reduction in lactoferrin preparations and lactoferrin containing compositions
WO2005087929A1 (en) * 2004-03-15 2005-09-22 Tissugen Pty Ltd Infectious aetiology of prostatic disease and methods to identify causative agents
EP2308566B1 (en) * 2005-04-08 2017-07-05 The Procter and Gamble Company Use of orally administered probiotic bifidobacteria for human beauty benefits
MX2007012697A (es) * 2005-04-13 2008-01-14 Nestec Sa Formula para infantes con probioticos.
US20060233762A1 (en) * 2005-04-15 2006-10-19 Mcmahon Robert J Method for treating or preventing systemic inflammation in formula-fed infants
US20060233752A1 (en) * 2005-04-15 2006-10-19 Mcmahon Robert J Method for treating or preventing systemic inflammation in formula-fed infants
WO2006124630A2 (en) * 2005-05-13 2006-11-23 New England Medical Center Hospitals, Inc. Compositions and methods for enhancing the efficacy of vaccines
ES2388198T5 (es) * 2007-02-28 2020-07-14 Mjn Us Holdings Llc Lactobacillus Rhammosus GG inactivado para tratar la inflamación sistémica en bebés

Also Published As

Publication number Publication date
MY145769A (en) 2012-04-13
US9408818B2 (en) 2016-08-09
MY151892A (en) 2014-07-14
US20080206213A1 (en) 2008-08-28
EP2114423B1 (en) 2012-06-06
ATE544457T1 (de) 2012-02-15
HK1136969A1 (en) 2010-07-16
RU2468808C2 (ru) 2012-12-10
CN105796607A (zh) 2016-07-27
ES2388198T3 (es) 2012-10-10
TW200906426A (en) 2009-02-16
ES2381232T3 (es) 2012-05-24
CA2679374C (en) 2016-05-31
EP2114423B2 (en) 2020-01-01
EP2124977B9 (en) 2012-05-02
CA2676956C (en) 2017-06-13
RU2009135871A (ru) 2011-04-10
MX2009008875A (es) 2009-08-28
US9408819B2 (en) 2016-08-09
ES2388198T5 (es) 2020-07-14
WO2008106372A1 (en) 2008-09-04
EP2124977B1 (en) 2012-02-08
EP2114423A1 (en) 2009-11-11
TWI418355B (zh) 2013-12-11
BRPI0808145A2 (pt) 2021-03-23
BRPI0808052A2 (pt) 2014-06-24
PL2114423T3 (pl) 2012-10-31
WO2008106373A1 (en) 2008-09-04
PL2124977T3 (pl) 2012-07-31
RU2009135873A (ru) 2011-04-10
US20080206212A1 (en) 2008-08-28
TW200900075A (en) 2009-01-01
TWI494114B (zh) 2015-08-01
CN101678053A (zh) 2010-03-24
HK1141729A1 (zh) 2010-11-19
CN101636172A (zh) 2010-01-27
RU2468807C2 (ru) 2012-12-10
CN101678053B (zh) 2015-12-16
CA2676956A1 (en) 2008-09-04
EP2124977A1 (en) 2009-12-02
CA2679374A1 (en) 2008-09-04

Similar Documents

Publication Publication Date Title
MY145769A (en) Method for treating or preventing systemic inflammation
MX2010006823A (es) Metodos para el tratamiento de la gota.
EA201300860A1 (ru) Кристаллические трипептидные ингибиторы эпоксикетон-протеазы
MY147175A (en) Method for preventing or treating the development of respiratory allergies
CY1115852T1 (el) Φαρμακευτικες συνθεσεις
MX350745B (es) El uso de un compuesto de carbamoilo para el tratamiento del sindrome de fibromialgia.
WO2012156531A9 (en) Lysine demethylase inhibitors such as cyclylcylopropamine derivatives for use in the treatment of inflammatory diseases or conditions
MX2015002371A (es) Inhibidores bivalentes de las proteinas iap y metodos terapueticos que usan los mismos.
MY176031A (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
WO2009158432A3 (en) Ang-2 inhibition to treat multiple sclerosis
NZ596916A (en) Treatment of portal hypertension and restoration of liver function using l-ornithine phenylacetate
WO2009079451A3 (en) Compositions and methods of promoting wound healing
ECSP10010446A (es) Uso de ranolazina para el tratamiento del dolor
MY149028A (en) Nalmefene hydrochloride dihydrate
MX348941B (es) Medios y metodos para trata y/o prevenir el cancer dependiente del ligando natural de receptor de aril-hidrocarburo.
MX2010002734A (es) Derivados de 1-amino-alquilciclohexano para el tratamiento y prevencion de perdida auditiva.
NZ700399A (en) Boronic acid conjugates of oligonucleotide analogues
UA100702C2 (ru) Комбинационная терапия рака поджелудочной железы с использованием антигенного пептида и химиотерапевтического средства - гемцитабина
TW200716146A (en) Method for treating or preventing systemic inflammation in formula-fed infants
PL2099769T3 (pl) Związki 6-okso-1,6-dihydropirymidyn-2-ylowe do leczenia chorób proliferacyjnych
TW200724146A (en) Use of LGG in the manufacture of a medicament for the treatment, prevention or reduction of systemic inflammation in a formula-fed infant
PH12016500497A1 (en) Compositions for the treatment of hypertension and/or fibrosis
GB0710536D0 (en) Plant extract and its therapeutic use
WO2006081371A3 (en) Combination therapy with triterpenoid compounds and proteasome inhibitors
WO2007100435A3 (en) Use of dha and ara in the preparation of a composition for the prevention or treatment of anemia

Legal Events

Date Code Title Description
FG Grant or registration
GB Transfer or rights